Amiram Goldblum

The Hebrew University of Jerusalem, Israel

Title: In silico discovery of multitargeted drug candidates

---

Biography

Studied Chemistry and Physics followed by a PhD in Organic Chemistry at the Hebrew University of Jerusalem (With Prof. R. Mechoulam). Subsequently a postdoctoral fellow at the Institute for Physico-Chemical Biology in Paris, studying Quantum Biochemistry (with Profs. Alberte and Bernard Pullman), at Pomona College, Claremont, CAL studying Quantitative Structure-Activity Relations (with Prof. Corwin Hansch) and at Stanford University, Palo Alto, CAL, studying computational reaction mechanisms of enzymes (with Dr. Gilda Loew). Goldblum is currently the head of the Molecular Modeling and Drug Design unit at the Institute for Drug Research of the Hebrew University of Jerusalem, and a member of the Fraunhofer Project center for Drug Design and Delivery. Goldblum invented a prize winning algorithm (American Chemical Society, 2000, Kaye Innovation prize 2017) which his group employs for all drug discovery projects. 

Abstract

We apply our own algorithms and those of others to discover novel drug candidates, with multitargeting of single molecules as a main goal in complex disease conditions. We model several targets as well as anti-targets in many different and diverse projects such as new antobiotics (our nano-mupirocin is currently developed in RebioticsRX,  PPARdelta agonists, CB1R and CB1R dual (obesity, licensed to BioNanoSim, Jerusalem), TLR9 (and Dual TLR9/TLR7) with Fraunhofer Institute, non-hormonal contraceptives (Gates Foundation supported)  PCSK9 blockers in ribosomes and for interactions with LDLR,  SARS-2 blockers of Spike-ACE2 interactions and of the 3C-like protease, Sugar substitutes, multitargeting in Progeria, Crohn and Colitis, Epilepsia Dravet Syndrome and Alzheimer’s Disease.

All projects are performed in collaborations with experimentalists.